LG Life Sciences, the biopharmaceuticals unit of the LG Group, will start selling the nation’s first diabetes treatment Zemiglo in the global market in earnest.
In a bid to tap into the global market, the Korean drugmaker sealed a licensing partnership with French-based pharma giant Sanofi and Mexico’s Stendhal from 2013 to distribute and market the new diabetes drug in 104 countries globally. Also, it is carrying out clinical trials and seeking approval to sell the new diabetes drug through partnering firms in major countries of the world at the same time.
Accordingly, LG Life Sciences was licensed to sell Zemiglo in 9 countries, including India, last year. Starting with a launch symposium in Costa Rica, the company will begin releasing and selling the new diabetes treatment in five countries in Central America and India from March this year.
Exclusively developed by LG Life Sciences, Zemiglo is a Type II diabetes drug that lowers and controls a patient’s blood sugar levels as well as improves his urine albumin excretion rate. Delivering treatment effects under just one 50-milligram tablet a day without a dosage adjustment, the drug boasts heightened patient convenience.